![Restoration of Li+ pathways in the [010] direction during direct regeneration for spent LiFePO4](http://pubs.rsc.org/services/images/RSCpubs.ePlatform.Service.FreeContent.ImageService.svc/ImageService/image/GA?id=D5EE00641D)
.jpg)
STAT+: CRISPR company Arbor Biotechnologies gets cash infusion from ARCH
At a time when CRISPR companies have struggled, the Feng Zhang spinoff Arbor Biotechnologies gets a cash infusion to head to clinical trials.
Three years ago, Arbor Biotechnologies CEO Devyn Smith appeared at the J.P. Morgan Healthcare Conference and laid out a grand vision: With $215 million in new capital, the biotech would push forward CRISPR-based drugs for a series of liver and brain diseases, beginning by filing for a first trial in under two years.
It was, suffice to say, bold. Arbor had yet to even conduct a mouse experiment.
“I mean, we set very aggressive targets,” Smith said in a recent interview. “You don’t set aggressive targets, you don’t get aggressive wins.”
